Ensayos clínicos

1.365 ensayos encontrados

CompletadoFase 3ClinicalTrials.gov

LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy

IntervencionalInicio: 5 de mar de 2012ID: NCT01523587

Activo, no reclutaClinicalTrials.gov

Ensayo colaborativo de niraparib para evaluar pacientes con cáncer de ovario en el Programa de Acceso Expandido en América Latina

ObservacionalInicio: 21 de jul de 2023ID: NCT05857397

CompletadoFase 3ClinicalTrials.gov

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

IntervencionalInicio: 1 de mar de 2010ID: NCT01014208

CompletadoClinicalTrials.gov

A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients With Early Stage Cervical Cancer

IntervencionalInicio: 1 de ene de 2008ID: NCT00614211

DesconocidoClinicalTrials.gov

Real World Evidence of Brentuximab Vedotin Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant

ObservacionalInicio: 1 de jun de 2021ID: NCT04776265

CompletadoFase 3ClinicalTrials.gov

A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)

IntervencionalInicio: 1 de jul de 2004ID: NCT00087022

CompletadoFase 2ClinicalTrials.gov

A Phase II, Randomized Double-blind, 2-part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa™) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-small Cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.

IntervencionalInicio: 1 de may de 2003ID: NCT00059722

CompletadoFase 2ClinicalTrials.gov

Estudio de discontinuación aleatoria de brivanib alaninate (BMS-582664) versus placebo en sujetos con tumores avanzados

IntervencionalInicio: 1 de jun de 2008ID: NCT00633789

CompletadoFase 3ClinicalTrials.gov

A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.

IntervencionalInicio: 1 de may de 2009ID: NCT01095003

TerminadoFase 3ClinicalTrials.gov

Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.

IntervencionalInicio: 1 de dic de 2008ID: NCT00761280

CompletadoFase 3ClinicalTrials.gov

A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

IntervencionalInicio: 9 de mar de 2016ID: NCT02677896

CompletadoFase 4ClinicalTrials.gov

A Phase 4 Study in the Treatment of Anemia With Weekly Epoetin Alfa Doses in Patients With Solid Tumors or Lymphoma Receiving Chemotherapy

IntervencionalInicio: 1 de jun de 2011ID: NCT01374373

CompletadoFase 3ClinicalTrials.gov

A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

IntervencionalInicio: 22 de nov de 2010ID: NCT01245062

CompletadoFase 3ClinicalTrials.gov

A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy

IntervencionalInicio: 5 de ene de 2012ID: NCT01345682

CompletadoFase 3ClinicalTrials.gov

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer

IntervencionalInicio: 1 de ene de 2004ID: NCT00075270

Activo, no reclutaFase 3ClinicalTrials.gov

Estudio de fase 3, abierto y aleatorizado de lazertinib con amivantamab subcutáneo comparado con amivantamab intravenoso en pacientes con cáncer de pulmón de células no pequeñas avanzado o metastásico con mutación de EGFR tras progresión con osimertinib y quimioterapia

IntervencionalInicio: 5 de ago de 2022ID: NCT05388669

Activo, no reclutaFase 3ClinicalTrials.gov

Estudio aleatorizado, abierto, de fase 3 para evaluar zimberelimab y domvanalimab en combinación con quimioterapia versus pembrolizumab con quimioterapia para el tratamiento de primera línea de pacientes con cáncer de pulmón de células no pequeñas metastásico sin aberraciones genómicas tumorales en el receptor del factor de crecimiento epidérmico o en la quinasa del linfoma anaplásico

IntervencionalInicio: 12 de oct de 2022ID: NCT05502237

CompletadoFase 3ClinicalTrials.gov

A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

IntervencionalInicio: 23 de may de 2017ID: NCT03069352

CompletadoClinicalTrials.gov

Estudio observacional de la seguridad y eficacia de obinutuzumab en pacientes con leucemia linfocítica crónica tratados en Argentina

ObservacionalInicio: 31 de ago de 2017ID: NCT03059251

Activo, no reclutaFase 3ClinicalTrials.gov

Estudio global, de fase III, aleatorizado, abierto, controlado y multicéntrico de durvalumab en primera línea en combinación con quimioterapia estándar y durvalumab en combinación con tremelimumab y quimioterapia estándar versus quimioterapia estándar sola en pacientes con cáncer urotelial localmente avanzado irresecable o metastásico.

IntervencionalInicio: 27 de sept de 2018ID: NCT03682068